RESEARCH TRIANGLE PARK, N.C. , March 09, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that 2020 financial results will be reported on Tuesday, March 23, 2021 . The company will host a webcast and conference call at 8:30 a.m.
RESEARCH TRIANGLE PARK, N.C. , March 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the closing of a debt facility on February 26, 2021 , with Silicon Valley Bank , which provides Liquidia with up to $20.5 million in term loans of which the first $10.5 million was
RESEARCH TRIANGLE PARK, N.C. , Dec. 14, 2020 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Damian deGoa has been appointed as Chief Executive Officer (CEO) and a director of the Company, effective immediately. He succeeds Neal F.
RESEARCH TRIANGLE PARK, N.C. , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Michael Kaseta has been appointed Chief Financial Officer (CFO), effective immediately. He succeeds Steve Bariahtaris who has served as Liquidia’s interim CFO since August 2020 . Mr.
CRL does not cite need for additional clinical studies CRL focuses on drug CMC and device biocompatibility information Conference Call Scheduled for Today at 9:00a . m . ET RESEARCH TRIANGLE PARK, N.C. , Nov. 25, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc.
Merger Reinforc es Company’s Commitment to Patients with PAH Paul Manning and Roger Jeffs Join Liquidia Corporation Board of Directors RESEARCH TRIANGLE PARK, N.C. , Nov. 18, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company
Stockholders Approve RareGen Acquisition Merger Expected to Close on or A bout November 18 , 2020 RESEARCH TRIANGLE PARK, N.C. , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and
RESEARCH TRIANGLE PARK, N.C. , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal
- Raised $75 M illion through Underwritten Public Offering - Bolstered and Defended LIQ861 Patent Position - Advanced Efforts in Support of the RareGen, LLC Merger and Integration - Company to Host Webcast and Conference Call Today at 8:00 a.m. ET RESEARCH TRIANGLE PARK, N.C. , Nov.
Company Determines Unsolicited Offer does not Constitute Superior Proposal RESEARCH TRIANGLE PARK, N.C , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products